Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anthim (Obiltoxaximab) Field Study for Inhalational Anthrax
NCT03088111Phase 4Not yet recruiting
- Sponsor
- Elusys Therapeutics
- Start
- Dec 2023
- Primary completion
- Dec 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
A Phase 4 trial of obiltoxaximab in inhalational anthrax, sponsored by Elusys Therapeutics. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
obiltoxaximab
03
Conditions
inhalational anthrax
Beyond the preview
Go deeper on NCT03088111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03088111.